Your browser doesn't support javascript.
loading
The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models.
Masanas, Marc; Masiá, Nuria; Suárez-Cabrera, Leticia; Olivan, Mireia; Soriano, Aroa; Majem, Blanca; Devis-Jauregui, Laura; Burgos-Panadero, Rebeca; Jiménez, Carlos; Rodriguez-Sodupe, Pau; Boloix, Ariadna; Toledano, Ignasi; Guillén, Gabriela; Navarro, Alexandra; Llobet-Navas, David; Villanueva, Alberto; Sánchez de Toledo, Josep; Roma, Josep; Noguera, Rosa; Moreno, Lucas; Krauss, Rolf; Gallego, Soledad; Santamaria, Anna; Segura, Miguel F.
Afiliación
  • Masanas M; Group of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Masiá N; Cell Cycle and Cancer Laboratory, Biomedical Research Group in Urology, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Suárez-Cabrera L; Cell Cycle and Cancer Laboratory, Biomedical Research Group in Urology, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Olivan M; Cell Cycle and Cancer Laboratory, Biomedical Research Group in Urology, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Soriano A; Translational Oncology Laboratory, Anatomy Unit, Department of Pathology and Experimental Therapy, School of Medicine, Universitat de Barcelona (UB), L'Hospitalet de Llobregat, Spain.
  • Majem B; Group of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Devis-Jauregui L; Cell Cycle and Cancer Laboratory, Biomedical Research Group in Urology, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Burgos-Panadero R; Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.
  • Jiménez C; Group of Translational Research in Pediatric Solid Tumors Department of Pathology, Medical School, University of Valencia-INCLIVA Biomedical Health Research Institute, Valencia, Spain.
  • Rodriguez-Sodupe P; Low Prevalence Tumors. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
  • Boloix A; Group of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Toledano I; Quantitative Genomic Medicine Laboratory, qGenomics, Barcelona, Spain.
  • Guillén G; Group of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Navarro A; Cell Cycle and Cancer Laboratory, Biomedical Research Group in Urology, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Llobet-Navas D; Group of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Villanueva A; Department of Surgery, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Sánchez de Toledo J; Department of Pathology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Roma J; Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.
  • Noguera R; Low Prevalence Tumors. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
  • Moreno L; Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.
  • Krauss R; Xenopat S.L., Business Bioincubator, Bellvitge Health Science Campus, Barcelona, Spain.
  • Gallego S; Group of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Santamaria A; Catalan Institute of Oncology (ICO), Barcelona, Spain.
  • Segura MF; Group of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Clin Transl Med ; 11(10): e533, 2021 10.
Article en En | MEDLINE | ID: mdl-34709738
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Cinesinas / Neuroblastoma / Antineoplásicos Límite: Animals / Humans Idioma: En Revista: Clin Transl Med Año: 2021 Tipo del documento: Article País de afiliación: España
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Cinesinas / Neuroblastoma / Antineoplásicos Límite: Animals / Humans Idioma: En Revista: Clin Transl Med Año: 2021 Tipo del documento: Article País de afiliación: España